Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO GuidelineYu‐Pei Chen, A. Dimitrios Colevas, Robert I. Haddad et al.|Journal of Clinical Oncology|2021Cited by 393
STAT3 activation contributes directly to Epstein‐Barr virus–mediated invasiveness of nasopharyngeal cancer cells <i>in vitro</i>Vivian Wai Yan Lui, Anthony T.�C. Chan|International Journal of Cancer|2009Cited by 70
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of responseBrigette Ma, Anthony T.�C. Chan|Investigational New Drugs|2009Cited by 44
Barriers to clinical trial recruitment in head and neck cancerRobert I. Haddad, Jan B. Vermorken, Anthony T.�C. Chan|Oral Oncology|2015Cited by 40
Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinomaChi Hang Wong, Anthony T.�C. Chan|Scientific Reports|2018Cited by 34